Meridian Bioscience

The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.

Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.

Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.

The firm saw modest growth in both its life science and diagnostics divisions and increased its guidance for the year.

The firm saw double-digit growth in both its core diagnostics and life sciences businesses, with losses in its Magellan lead testing division.

The firm saw a 6 percent increase in fiscal fourth quarter revenues, with growth in both its diagnostics and life science segments.

The firm attributes the positive results to efforts to strengthen its US diagnostics business and stabilize its core diagnostics product families of H. pylori and food testing.

The Index fell less than 1 percent in July, underperforming the Dow, the Nasdaq, and the Nasdaq Biotechnology Index.

The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent.